86 studies found for:    "Neisseria meningitidis"
Show Display Options
Rank Status Study
1 Recruiting Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC)
Condition: Neisseria Meningitidis
Intervention: Biological: MenBvac
2 Completed
Has Results
Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine
Conditions: Meningitis;   Meningococcemia;   Neisseria Meningitidis
Intervention: Biological: A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)
3 Completed
Has Results
Dose Comparison Study of Menactra® in US Children
Conditions: Meningitis;   Meningococcal Infection;   Neisseria Meningitidis
Intervention: Biological: Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate
4 Completed
Has Results
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.
Conditions: Meningococcal Infection;   Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine;   Haemophilus Influenza b Infections
Interventions: Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014);   Biological: PedvaxHIB;   Biological: Prevnar;   Biological: M-M-R II;   Biological: Varivax
5 Completed
Has Results
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age
Conditions: Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine;   Haemophilus Influenza Infections
Interventions: Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014;   Biological: ActHIB;   Biological: Pediarix/Infanrix Penta
6 Completed Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.
Condition: Invasive Neisseria Meningitidis Serogroup Diseases
Intervention: Biological: Meningococcal vaccine GSK134612
7 Completed
Has Results
Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014
Condition: Invasive Disease Caused by Neisseria Meningitidis Due to Serogroups A, C, W-135, Y
Interventions: Biological: GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix);   Biological: GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix);   Biological: Infanrix®;   Biological: ActHIB®;   Biological: Pediarix®
8 Completed
Has Results
Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.
Conditions: Haemophilus Influenzae Type b;   Neisseria Meningitidis
Interventions: Biological: Haemophilus influenzae type b and meningococcal serogroup C (vaccine);   Biological: Priorix™;   Biological: Hiberix™;   Biological: Meningitec™
9 Completed
Has Results
Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine
Conditions: Haemophilus Influenzae Type b;   Neisseria Meningitidis
Interventions: Biological: GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine;   Biological: ActHIB;   Biological: Pediarix;   Biological: Prevnar;   Biological: Menomune
10 Completed
Has Results
Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia
Conditions: Neisseria Meningitidis;   Meningococcal Infections
Interventions: Biological: Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine;   Biological: Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine
11 Completed NeisVac-C Single Prime Study in Infants
Condition: Neisseria Meningitidis
Interventions: Biological: Meningococcal group C polysaccharide conjugate vaccine;   Biological: Pneumococcal 13-valent conjugate vaccine;   Biological: Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine
12 Active, not recruiting Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination
Conditions: Neisseria Meningitidis;   Bacterial Infections;   Virus Diseases
Interventions: Biological: Hexavalent vaccine;   Biological: NeisVac-C;   Biological: Prevenar 13;   Biological: RotaTeq;   Biological: Nimenrix;   Biological: M-M-RVAXPRO
13 Completed
Has Results
Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines
Conditions: Neisseria Meningitidis;   Haemophilus Influenzae Type b
Interventions: Biological: MenitorixTM;   Biological: Pneumococcal conjugate vaccine GSK1024850A;   Biological: PrevenarTM;   Biological: MeningitecTM;   Biological: NeisVac-CTM;   Biological: InfanrixTM hexa;   Biological: InfanrixTM penta;   Biological: InfanrixTM IPV/Hib;   Biological: InfanrixTM IPV
14 Completed Immunogenicity and Safety of V419 Given at 2, 3 and 4 Months of Age With Meningococcal Serogroup C Conjugate Vaccines
Conditions: Neisseria Meningitidis;   Bacterial Infections;   Virus Diseases
Interventions: Biological: V419 (PR5I);   Biological: Prevenar 13;   Biological: NeisVac-C;   Biological: MENJUGATE;   Biological: MENITORIX;   Biological: M-M-RVAXPRO
15 Active, not recruiting Spanish Mixed HEXA/PENTA/HEXA Schedule
Conditions: Neisseria Meningitidis;   Bacterial Infections;   Virus Diseases
Interventions: Biological: PR5I (V419);   Biological: Pediacel;   Biological: NeisVac-C;   Biological: RotaTeq;   Biological: Prevenar 13
16 Recruiting Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age
Conditions: Neisseria Meningitidis;   Haemophilus Influenzae Type b
Interventions: Biological: Hib-MenCY-TT vaccine (GSK792014);   Biological: Pediarix®;   Biological: Rotarix®;   Biological: Prevnar 13®;   Biological: PedvaxHIB®;   Biological: Havrix®
17 Completed Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults
Condition: Neisseria Meningitidis
Intervention: Biological: Meningococcal outer membrane vesicle vaccine "MenBVac"
18 Completed N. Meningitidis Carriage Study
Condition: Infections, Meningococcal
Interventions: Procedure: Posterior pharyngeal swab;   Other: Data collection
19 Completed Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants
Conditions: Hib Disease;   Hepatitis B;   Diphtheria;   Pertussis;   Neisseria Meningitidis Serogroup Diseases;   Tetanus
Intervention: Biological: DTPw-HBV/Hib-MenAC conjugate vaccine
20 Completed Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth
Conditions: Hib Disease;   Hepatitis B;   Diphtheria;   Pertussis;   Neisseria Meningitidis Serogroup Diseases;   Tetanus
Intervention: Biological: DTPw-HBV/Hib-MenAC conjugate vaccine

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years